Transplantation surgery

25 Transplantation surgery






Transplant immunology


The basis of transplant immunology is the host’s recog-nition of foreign tissue and its subsequent response to that. Our understanding of the molecular basis of this response has developed significantly over the last 50 years, which has allowed clinical transplantation to expand enormously. The process of transplant rejection, caused by infiltrating leucocytes, exhibits both specificity and memory and is prevented by lymphocyte depletion. The major histocompatibility complex (MHC) encodes the predominant transplant antigens responsible for acute rejection, and these are identical to serologically defined human leucocyte antigens (HLA).



The recipient’s immune response to the donor organ



Early events


Inflammation lies at the heart of the rejection process and is activated through early events around the time of transplantation. Brain-stem death and retrieval of organs, as well as cold ischaemic time (while the organ is stored on ice) and a period of warm ischaemia (while the vascular anastomoses are completed) stimulate an early inflammatory response to the transplanted organ. Reperfusion is associated with endothelial activation and the infiltration of inflammatory cells, particularly macrophages. The importance of this early ischaemia reperfusion injury (IRI) in shaping the patient’s subsequent course is illustrated by the superior outcome observed following living donor transplantation, despite more significant major histocompatibility (MHC) mismatching, and the adverse impact of a more prolonged cold ischaemic time on graft outcome. Indeed, the severity of this inflammatory injury modulates the subsequent alloimmune response, generating a ‘danger signal’ which primes the immune response to the transplanted organ. Thus, IRI impacts upon long-term outcome: it leads to a delay in primary graft function, increases acute rejection rates and reduces long-term graft survival (EBM 25.2). The crucial role of IRI in mediating transplant-associated injury has become more apparent as acute rejection rates fall with the introduction of new and highly effective immunosuppressive agents, and has led to an increasing interest in how IRI may be reduced through preconditioning strategies.





Antigen presentation


Donor MHC antigens are recognized as foreign (allo- recognition) by recipient T cells following presentation upon donor (direct) or recipient (indirect) antigen-presenting cells (APCs) (Fig. 25.1).







Patterns of allograft rejection






Testing for histocompatibility


The immune system has evolved specifically to recognize and destroy harmful agents such as bacteria and viruses, but it is this in turn which has acted as an obstacle to successful allotransplantation. There are two main genetic systems involved: ABO blood groups and the human leucocyte antigen (HLA) system. There are two classes of HLA genes involved in the immune response to transplantation, class I and II. Potential donors and recipients are tested for class I (HLA-A, B and Cw) and class II (HLA-DR, DQ and DP) to facilitate organ allocation, such that the national allocation system for kidney transplantation places high priority on HLA matching, as the better match the kidney is to the recipient, the better the outcome.


In addition to this tissue typing process, a cross-match is undertaken immediately prior to renal transplantation to ensure that there is no reactivity between donor and recipient cells. There are two types of cross-match techniques: the complement-dependent cytotoxicity cross-match (CDC-XM), which, when positive in the presence of IgG antibodies, is likely to result in rapid rejection of the transplanted kidney. The flow cytometry cross-match (FC-XM) is a more sensitive test, which, if positive, may represent an increased risk of rejection. A decision should then be made as to whether or not to proceed with transplant following discussion between surgical and histocompatibility experts. The FC-XM is clinically relevant only in renal transplantation.




Immunosuppressive drugs





Calcineurin inhibitors (CNIs)








The future of immunosuppression


Tolerance is defined as the coexistence of a transplanted organ or tissue within a recipient without the need for continuous, long-term immunosuppression, whilst maintaining an otherwise intact immune system, and is one of the major goals of transplant research.


Other, perhaps more realistic goals of treatment, are to reduce the use of corticosteroids, and of CNIs. Several groups have explored steroid withdrawal, undertaken some time after transplantation, steroid avoidance, in which steroids are stopped a few day postoperatively and steroid-free regimens. Whilst the benefits of reduced steroid use have been observed in these studies, steroid-free and steroid-withdrawal were associated with increased incidence of biopsy-proven acute rejection at 12 months post-transplant.


Complete CNI elimination has been associated with higher rejection rates, without improvements in renal or metabolic side effects. The ELITE symphony study compared low dose CYA, low dose tacrolimus, low dose sirolimus and standard dose tacrolimus, and demonstrated superiority in the low dose tacrolimus group, in terms of acute rejection, renal function and allograft survival at one year.




Organ donation


The shortage of organs for transplantation remains a major challenge to the transplant community, with demand consistently outstripping supply over many years (Fig. 25.3). Such a shortage has led to significant changes in practice over the last decade, with an increasing number of patients undergoing transplants from living donors, and from marginal or extended criteria deceased donors. These will be discussed in this section.




Deceased donation


The identification and selection of potential donors and the subsequent approach to the family has been the focus of much attention within the United Kingdom. A UK Organ Donor Taskforce has made a series of recommendations which are aimed at increasing donor numbers. The donor transplant co-ordinators, now known as Specialist Nurses in Organ Donation, play a pivotal role in organ donation; they are now embedded within critical care areas, involved in the education of critical care staff on organ donation and transplantation, in addition to their key roles in donor management and discussion with donor families.


Current UK legislation is based on an ‘opt in’ policy, so that lack of objection must be obtained from the family in order to proceed. Other countries adopt an ‘opt out’ policy of presumed consent. There is a real need to raise public awareness of organ donation and to encourage individuals to carry organ donor cards.


Few absolute contraindications for organ donation exist; those that do are directed against the avoidance of disease transmission from donor to recipient (Table 25.3).


Table 25.3 Donor contraindications to organ donation













General contraindications
Organ-specific donor contraindications
Liver
Kidney
Pancreas


Donor management


Specific criteria must be met in order to make the diagnosis of brain-stem death (Table 25.4). Events leading up to brain death may impact upon the quality of the retrieved organs. Initially, at the point of brainstem death, compression associated with coning results in hypertension and bradycardia, known as the Cushing reflex. An autonomic storm ensues, characterized by the massive release of catecholamines, with resultant hypertension and hypoperfusion. The effect on cardiac function is the deterioration of ventricular systolic function, the liver and kidneys are affected by hypoperfusion, and it is likely that these changes contribute to non-specific endothelial cell damage, which increases the immunogenicity of the organs.


Table 25.4 Criteria for diagnosis of brain-stem death











Preconditions
Exclusions
Investigation
Absent brain-stem reflexes

Stay updated, free articles. Join our Telegram channel

Mar 20, 2017 | Posted by in GENERAL SURGERY | Comments Off on Transplantation surgery

Full access? Get Clinical Tree

Get Clinical Tree app for offline access